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Abstract
Background
Huntington’s disease (HD) is an autosomal dominant neurodegenerative condition caused
by an expanded CAG repeat in the gene encoding huntingtin (HTT). Optimizing peripheral
quantification of huntingtin throughout the course of HD is valuable not only to illuminate the
natural history and pathogenesis of disease, but also to detect peripheral effects of drugs in
clinical trial.
Rationale
We previously demonstrated that mutant HTT (mHTT) was significantly elevated in purified
HD patient leukocytes compared with controls and that these levels track disease progres-
sion. Our present study investigates whether the same result can be achieved with a simpler
and more scalable collection technique that is more suitable for clinical trials.
Methods
We collected whole blood at 133 patient visits in two sample sets and generated peripheral
blood mononuclear cells (PBMCs). Levels of mHTT, as well as N-, and C-terminal and mid-
region huntingtin were measured in the PBMCs using ELISA-based Meso Scale Discovery
(MSD) electrochemiluminescence immunoassay platforms, and we evaluated the relation-
ship between different HTT species, disease stage, and brain atrophy on magnetic reso-
nance imaging.
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Conclusions
The assays were sensitive and accurate. We confirm our previous findings that mHTT
increases with advancing disease stage in patient PBMCs, this time using a simple collec-
tion protocol and scalable assay.
Introduction
Huntington’s disease is a devastating neurodegenerative disease caused by a CAG
repeat expansion in exon 1 of the HTT gene, encoding an expanded polyglutamine in
the ubiquitously-expressed HTT protein. Mutant HTT (mHTT) expression is the primary
pathogenic factor for the development of HD, with increasing expression levels associated
with disease severity and toxicity in various models [1–3]. HD is autosomal dominant and
fully penetrant, which, combined with the availability of a genetic test, makes the disease
highly tractable [4–8]; however, biofluid biomarkers are limited [9]. There are currently no
disease-modifying therapies for HD but putative therapeutic approaches aim to lower
mHTT levels in the CNS [3], with the first trial of a HTT-lowering drug entering Phase 1/
2a trial in 2015 [10]. Peripheral biomarkers would further improve the understanding of
HD natural history, and could be sensitive to peripherally-administered therapies. Thus
though quantification of mutant and wild-type Huntingtin and their cleaved or truncated
species in living Huntington’s disease (HD) patients is challenging, it remains a desirable
objective.
Blood is readily available, and since peripheral immune system dysfunction is a feature of
HD and tracks disease progression [11–15], blood-based biomarkers are an area of interest.
We previously used a time-resolved Fo¨rster resonance energy transfer (TR-FRET) immunoas-
say to demonstrate that mHTT was significantly elevated in purified HD patient monocytes
and lymphocytes compared to controls, increased progressively with advancing disease stage,
and was associated with both disease burden score and caudate atrophy rate [13]. A disadvan-
tage of this technique is its dependence on FRET distance, which creates an unpredictable
relationship between CAG repeat length, protein concentration and FRET signal. Further-
more, the initial processing required to obtain purified leukocyte subpopulations is relatively
complicated, making it challenging to apply to multi-site clinical trial settings. We recently
described assays that measure either polyglutamine-independent human HTT or polygluta-
mine-expanded human HTT proteins on the electrochemiluminescence Meso Scale Discovery
(MSD) detection platform, and demonstrated that these assays are sensitive and selective in
model systems [16]. This MSD platform enables multiple states or species of HTT to be mea-
sured in complex tissues and fluids by using epitope-directed antibodies, and is more suited to
high-throughput studies.
Our work here explores whether the mHTT trends associations described above which
were detected in leukocyte subpopulations [13] could also be detected sensitively and accu-
rately for the first time in mixed leukocytes from HD patient samples using the MSD assay sys-
tem. We used a simple blood collection protocol that could be readily used at multiple study
sites as part of large-scale clinical trials: sampling tubes allow isolation of peripheral blood
mononuclear cells (PBMCs, including lymphocytes and monocytes) using a single-step pro-
cess [17–19]. Using the MSD platform assays we used different antibody combinations to
detect (1) polyglutamine-expanded (mutant) N-terminal HTT, (2) polyglutamine-indepen-
dent HTT N-terminus, (3) polyglutamine-independent HTT mid-region, and (4)
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polyglutamine-independent HTT C-terminus of HTT [16] (Fig 1). We then characterized the
relationship between HTT species, disease stage, and brain imaging variables.
Materials and methods
Study design and subject selection
Two cross-sectional studies were conducted nine months apart with a total of 133 visits from
101 participants (32 subjects were assessed on both visits) (Table 1 and S1 Table).
Subjects were recruited from the patients and relatives attending the multidisciplinary Hun-
tington’s disease clinic at the National Hospital for Neurology and Neurosurgery, University
College London Hospitals NHS Trust; some subjects were also participants in the TrackOn-
HD [20] or PADDINGTON studies [21] and had brain imaging available. Informed consent
was obtained from all participants, and the study was conducted in accordance with the decla-
ration of Helsinki. Ethical approval to undertake these analyses was provided by the National
Research Ethics Service Committee London—Queen Square.
Biosample collection
8ml whole blood was collected in BD Vacutainer1 CPT™ Cell Preparation Tubes and pro-
cessed within two hours according to manufactures guidelines [19]. Briefly, tubes were centri-
fuged at 1500g for 20 min at 22˚C (with no brake) to fractionate the cells using gradient
density centrifugation. The cell layer was washed twice with cold phosphate buffered saline
before the PBMC pellet was snap frozen on dry ice and transferred to a -80˚C freezer until
analysis.
Fig 1. Schematic diagram showing the capture and detection antibody pairs for each assay. The huntingtin amino acid residue epitope to which the
antibodies bind are shown (not to scale). Poly-Q, polyglutamine region; Poly-P, proline rich region. Details of the antibodies are given in the text below.
https://doi.org/10.1371/journal.pone.0189891.g001
Table 1. Demographic details of sample sets used.
Sample set 1 Sample set 2 Number of subjects repeated
Control 20 (11) 23 (14) 13 (8)
Premanifest HD 14 (7) 23 (14) 7 (5)
Early HD 14 (7) 18 (7) 7 (3)
Moderate HD 8 (5) 13 (7) 5 (3)
Total 56 (30) 77 (42) 32 (19)
Breakdown of number of subjects from different subject groups included in each sample set. Number of females in brackets.
https://doi.org/10.1371/journal.pone.0189891.t001
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HTT protein MSD electrochemiluminescence assays
ELISA-based MSD electrochemiluminescence immunoassay platforms were used as previ-
ously described [16]. Huntingtin levels were measured by four different assays in PBMCs.
These four assays, which we have termed A, B, C and D, each used a combination of two anti-
bodies, one capture and one detection (Fig 1).
Detailed description of the antibodies other than pAb139 have been published [16]. Anti-
body epitope mapping is described with reference to GenBank Accession CAD38447.1; all the
antibodies used are raised to human huntingtin. Briefly, pAb137 (CHDI-90000137) is a rabbit
polyclonal antibody for HTT amino acids 4–19 (acetyl-LEKLMKAFESLKSFQQC-amide).
MW1 is a mouse monoclonal antibody against the expanded polyglutamine domain; Li
mapped the epitope to be around 10 glutamines [22]. pAb146 (CHDI-90000146) is a rabbit
polyclonal antibodies for HTT amino acids 54–70 (acetyl-QLPQPPPQAQPLLPQPQC-amide)
which corresponds to the polyproline region [16]. MAB2166 is a mouse monoclonal antibody
whose epitope has been mapped to a 15-amino acid region spanning amino acids 445–459
[23]. pAb139 (CHDI-90000139) is a rabbit polyclonal antibody raised using procedures similar
to pAb137 described in Macdonald et al. 2014 against a synthetic peptide corresponding to res-
idues 3109–3134 of the huntingtin protein, specifically acetyl-LDRRAFQSVLEVVAAPGSPY
HRLLTC-amide near the C-terminus.
Using combinations of these antibodies, specific areas of the huntingtin protein were tar-
geted (Fig 1). Assay A, which combines MW1 and pAb146 is specific for the polyglutamine-
expanded mutant HTT. The other three antibody combinations measure different segments
of polyQ-independent HTT. Notably, the N-terminal region assay, B, is polyglutamine-inde-
pendent. A further amplification step for assays A and B was included by using a biotinylated
anti-mouse or anti-rabbit antibody after the MW1 or pAb137 detection antibody incubation
respectively, followed by streptavidin-sulfoTAG detection [16].
For every estimated 5 μl pellet size, 100 μl of lysis buffer (0.2% Tween, 0.05% SDS, 0.1 mM
EDTA, 1mM PMSF, protease inhibitors in PBS) was added and cells were lysed by vortexing.
After clearing the lysate by centrifugation, total protein concentration was measured using a
bicinchoninic acid assay (BCA, ThermoScientific) according to standard procedures. A fixed
amount of lysate was used for the MSD assay, making up the total volume with lysis buffer.
To allow inter-sample comparison, signal was divided by plate background, then corrected
for protein loading volume (30 micrograms in sample set 1, 17 micrograms in set 2). The cor-
rected data were used for subsequent analysis. Standard curves were used to confirm that the
samples were within detection range, but because of HTT’s limited stability in solution they
were not used to normalise data.
All analyses were performed by operators blinded to subject group and disease stage.
Imaging
For a subset of subjects in sample set 2 who had undergone 3-Tesla volumetric MRI as a part
of another study (TrackOn-HD or PADDINGTON London cohorts), the relationship between
rates of caudate and whole brain atrophy and HTT species levels was examined. Atrophy rates
provide a quantifiable measure of disease-associated changes in brain volume [20]. Details of
imaging protocols and rigorous quality control procedures are provided elsewhere [20, 21].
In brief, follow-up scans were positionally matched to baseline images, and change over 36
months was calculated using the robust boundary shift integral technique [24, 25]. All bound-
ary shift integral changes were annualized before statistical analysis. All image analysis was car-
ried out by an observer blinded to subject identity and group.
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The effect of a 0.1 fold increase in HTT signal over background measure on imaging vari-
ables was estimated for each assay. Analysis was restricted to 17 subjects for whom imaging
was performed within 4 months of biosample collection.
Statistical analysis
To estimate the reliability of the assays, intra-class correlation (ICC) coefficients were used to
examine the proportion of total variance explained by between-subject variability. The larger
the coefficient, the less variability within subject relative to the variation between subjects, and
so the higher the reliability of the assay. A linear mixed model was fitted to the data at the indi-
vidual replicate level, and the ICCs estimated (early disease and moderate disease subjects
were combined). Standard errors for the 95% confidence intervals were calculated using the
delta method [26]. Analyses were adjusted for stage, age and sex and group to remove any
between-subject variability attributable to these factors.
Since the HTT measurements were a continuous measure, in order to quantify the associa-
tions with disease stage/burden after adjusting for covariates, ordinary least squares (OLS)
regression was used to analyse the data. Between-stage differences in HTT levels were analysed
adjusted for age and sex. The OLS regression analysis was performed using the mean of the
replicates for each protein type as the primary outcome: for the first sample, two readings were
averaged; for the second set, three readings were averaged. Linear contrasts, which are linear
combinations of parameters used to estimate quantities of interest, were used to determine the
difference between disease stage groups.
The disease burden score (DBS) which encapsulates the expected burden of pathology rela-
tive to the subject’s age and CAG repeat length [27], and correlates with clinical endpoints [5],
is calculated as: DBS = Age × [CAG-35.5]. As for the relationship with disease stage, to evaluate
the relationship between DBS and huntingtin species levels, OLS regression was used. In order
to fully understand this association it was necessary to consider adjustments for both age and
CAG in this model (in addition to sex), to see whether any unadjusted association with DBS
is driven simply by age, or CAG, or whether the interaction between the two (DBS) is also
important. To have more easily interpretable parameter estimates from this model, we centred
age at 50, CAG at 35.5, and entered a centred interaction term between age and CAG (Age
− 50)×(CAG − 35.5) in place of disease burden. The parameter estimates and standard errors
for age, sex and the interaction term are equivalent to what would have been found had DBS
been used in its original form; however this parameterisation gives better accuracy and more
useful interpretation of the estimate for CAG.
Cross sectional associations between imaging measures and HTT were similarly analysed
using OLS regression with adjustments for age, sex and CAG.
Results
The assays used in this study are reliable
Intra-class correlation coefficients (ICC) comparing the duplicate (1st sample set) or triplicate
(2nd sample set) samples demonstrated that the reliability of these assays was generally high:
ICCs were greater than 0.75 for all assays in the larger second sample set in which we ran the
assay three times (S2 Table). For the mHTT assay A in the second sample set the ICC was 0.83,
and the within subject standard deviation 1.04.
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Mutant HTT increases with advancing disease stage in two sample sets
Analysis of mHTT protein levels (assay A) across groups in both sample sets (Tables 2 and 3,
Fig 2) indicates soluble mHTT is detected at higher levels in mutation carriers compared with
controls. We confirm that, even in these heterogeneous cells from a small 8ml blood sample,
the mHTT level tends to increase with advancing disease stage, as previously reported [13].
There was a statistically significant linear trend (p<0.001) for this increase in both sample
sets. There were significant differences (p< 0.003) in the level of mHTT between all stages
of disease and controls (premanifest HD, early HD and moderate HD) in both sample sets
(Table 3). There were also significant differences in the level of mHTT between moderate and
premanifest HD in both sample sets, however the differences between moderate and early HD
only approached significance while early vs premanifest HD were not significant (Table 3).
Table 2. Results for each sample set and disease stage.
Sample set 1 Sample set 2
Assay
(Region)
A
Mutant HTT
C
HTT Mid region
A
Mutant HTT
B
HTT N terminus
C
HTT Mid region
D
HTT C terminus
Controls
n 20 20 23 23 23 23
mean 1.87 7.40 1.93 2.61 4.63 2.22
St. dev. 0.76 3.24 0.28 0.31 1.37 0.35
Premanifest
n 14 14 23 23 23 23
mean 3.03 5.42 2.69 2.56 4.50 2.17
St. dev. 1.11 1.79 0.39 0.39 1.38 0.34
Early HD
n 14 14 18 18 18 18
mean 3.30 6.11 2.97 2.71 5.03 2.13
St. dev. 1.32 2.76 0.77 0.46 1.57 0.28
Moderate HD
n 8 8 13 13 13 13
mean 4.12 7.17 3.29 2.86 5.28 2.40
St. dev. 0.89 1.97 0.75 0.46 1.66 0.49
Unit is assay signal over background. Refer to Fig 1 for details on the assays. (HTT = huntingtin; n = number of samples; St. dev. = standard deviation).
https://doi.org/10.1371/journal.pone.0189891.t002
Table 3. Comparison of mHTT levels in subjects with different disease stages.
Mutant HTT (Sample set 1, n = 56) Mutant HTT (Sample set 2, n = 77)
Estimate
(95% CI)
P value Estimate
(95% CI)
P value
Pre HD vs Controls 1.14 (0.43, 1.84) 0.002 0.73 (0.41, 1.06) <0.001
Early HD vs Controls 1.37 (0.63, 2.11) 0.001 0.98 (0.64, 1.32) <0.001
Moderate HD vs Controls 2.25 (1.3, 3.21) <0.001 1.34 (0.98, 1.71) <0.001
Moderate HD vs Pre HD 1.12 (0.07, 2.17) 0.038 0.61 (0.23, 1) 0.002
Moderate HD vs Early HD 0.88 (-0.03, 1.8) 0.058 0.37 (-0.02, 0.75) 0.062
Early vs Pre HD 0.23 (-0.6, 1.06) 0.576 0.25 (-0.11, 0.61) 0.176
Between-stage comparisons of mHTT levels in sample set 1 and 2 using Assay A. Age and sex adjusted. Total number of subjects for sample is indicated,
but number of subjects contributing to each comparison depends on the number of subjects in each stage (available in Table 1).
https://doi.org/10.1371/journal.pone.0189891.t003
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No robust relationship between poly-Q independent HTT species and
disease stage
Levels of poly-Q independent HTT mid-region species (Assay C) showed no clear trends
across groups in either sample set 1 or 2 (Fig 3). In the second sample set N-terminal (Assay B)
and C-terminal (Assay D) Huntingtin species were also examined: there was no association
with disease stage for either, except for a modest difference in C-terminal HTT between mod-
erate and early stage HD subjects (P = 0.026) (Fig 3).
Relationship between HTT species and CAG repeat length, disease
burden score and sex
In sample set 2 higher levels of mutant huntingtin were associated with a higher DBS when
only disease burden, age and sex were included in the model (p = 0.001). When the CAG
repeat was included as a covariate, the relationship with disease burden was no longer signifi-
cant, but the CAG term was, implying that increased CAG repeat length per se is associated
with a higher mHTT signal (Fig 4 and S3 Table). In the smaller sample set 1, estimates were
consistent with those found in the larger sample, but no statistically significant relationship
between mutant huntingtin levels and sex, DBS, age or CAG repeat length was found (Fig 4
and S3 Table).
There were no statistically significant relationships between DBS, CAG, age or sex for either
of the HTT mid-region assays (sample sets 1 and 2) (Fig 5 and S4 Table). Similarly there was
no relationship between C-terminal HTT and any of these outcome measures. However, for
total N-terminal HTT, in the fully adjusted model, DBS was found to be significantly associ-
ated with HTT (estimate 0.364, CI 0.035–0.694), as was CAG (estimate of effect of 1 unit
increase in CAG on N terminal HTT for subject age 50: 0.089, CI 0.023–0.155) (Fig 4B and S4
Table).
Unexpectedly, we found a significant relationship between sex and mHTT level such that
women had a slightly lower level of mHTT than men, in sample set 2 only. This has not been
found in previous studies and its significance is unclear, but consequently sex was included as
a covariate for all analyses.
Fig 2. Successful quantification of mHTT in PBMCs from 8ml whole blood in HD. These data confirm that mHTT levels in leukocytes are higher at
more advanced disease stages. Assay A (mHTT N-terminus assay) was used to selectively quantify mHTT: S/B, signal over background. A) Sample set 1
(mean of 2 replicates); (B) Sample set 2 (mean of 3 replicates).
https://doi.org/10.1371/journal.pone.0189891.g002
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Fig 3. Box plots showing average polyglutamine independent HTT levels across patient subgroups. (S/B:
Signal / Background) No significant differences are seen between HTT species levels and disease stage, other than
a difference in C-terminal HTT between Moderate and Early HD patients. (A) Distribution of Mid Region HTT (Assay
C) in sample group 1. (B) Distribution of Mid Region HTT (Assay C) in sample group 2. (C) Distribution of
polyglutamine-independent N terminal HTT (Assay B) in sample group 2. (D) Distribution of C terminal HTT
(polyglutamine-independent Assay D) in sample group 2.
https://doi.org/10.1371/journal.pone.0189891.g003
Fig 4. Association between DBS and mHTT (S/B: Signal/Background, mean of replicated samples) in sample set 1 (A) and 2 (B). P values
adjusted for age, sex and CAG.
https://doi.org/10.1371/journal.pone.0189891.g004
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No relationship seen between peripheral huntingtin species and brain
imaging measures
Analysis of associations between peripheral HTT levels and (a) the ratio of caudate to whole
brain volume as a percentage of the total intracranial volume, expressed as caudate/whole
brain volume (%TIV), or (b) caudate/whole brain atrophy rates for the year preceding the
sample, showed little evidence of association, though sample size was limited here (S5 Table).
Discussion
We have demonstrated that the MSD assays used in this study robustly detect mutant and
polyQ-independent HTT protein species from human blood with low inter-sample variability:
the ICC coefficients for the assays are high. These findings confirm that the previously-
described assays [16] are suitable for use in HD disease patient cohorts, enabling the study of
HTT species ex vivo.
The assays work on small volumes of blood and use unsorted PBMCs generated by a simple
processing protocol, meaning that these techniques would be useful for multisite clinical trials
and studies. Along with the increased dynamic range of MSD assays compared to other meth-
ods of HTT detection, the ability to multiplex assays in a high-throughput manner, and the
Fig 5. Association between HTT species level (S/B: Signal/Background, mean replicated samples) and disease
burden score; adjusted for age, sex and CAG. (A) HTT mid region in sample set 1, (B) N-terminal HTT in sample set 2,
(C) HTT mid region in sample set 2, (D) C-terminal HTT in sample set 2). Circles = premanifest, triangles = Early,
squares = Moderate.
https://doi.org/10.1371/journal.pone.0189891.g005
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high throughput on 96- or 384-well format, these assays are suitable for clinical trials in which
a peripheral HTT biomarker is important.
We have confirmed our previous finding that higher levels of mHTT are found in PBMCs
as HD progresses [13]. The antibody pair pAb146-MW1 specifically detects human HTT pro-
tein in a polyglutamine-dependent manner (assay A) [16]. However, we found a background
signal when using the MW1 antibody in controls that may be due to off-target background or
residual detection of the non-expanded protein by MW1, which recognizes a sequence of
approximately 10Qs in the HTT protein [22].
It is interesting that there was no statistically-significant relationship between polyQ inde-
pendent N-terminal fragments and disease stage in sample set 2. Assay B, the N-terminal pro-
tein assay using the pAb146-pAb137 antibody combination, enables the detection of both
wild-type and mutant HTT fragments. While the two antibodies are either side of the CAG
repeat, the assay is independent of polyglutamine length (Fig 1). Though there was a trend for
polyglutamine-dependent N-terminal fragments to increase with disease stage, polyglutamine
independent N-terminal fragments, including both expanded and non-expanded alleles did
not, suggesting that the observed increase with progression is mHTT-specific. The second
sample set also examined C-terminal HTT species and showed there was a significant, but
small, effect in C-terminal HTT between moderate and early stage subjects (P = 0.026), the
meaning of which is unclear.
The reason for increased mHTT levels in patients with advancing disease stage has not
been conclusively established, and putative explanations have been discussed [13]. The assays
rely on pairs of antibodies with epitopes at different points on HTT (Fig 1) and they may be
detecting either full-length HTT (mutant or wild type), smaller fragments of the protein that
encompass the antibody binding sites, or a possible combination of these two. The increase in
mHTT signal could reflect an increase in full-length or fragmented N-terminal species of
HTT; changes in tertiary/quaternary structure due to folding or complex formation resulting
in loss of epitope shielding; or somatic expansion of the CAG tract increasing the number of
glutamine residues[28, 29].
Our cell populations were short lived (as in Weiss et al,), so mHTT accumulation within
post-mitotic cells is unlikely: monocytes typically persist for 2–8 days [30], T-lymphocytes for
11–13 weeks [31] and B-lymphocytes for 10–12 weeks [32], with just a small fraction of lym-
phocytes persisting as memory cells. Haematopoeitic stem cells in bone marrow are life-long,
however, and may accumulate mHTT with ageing. The N-terminal species may be the product
of increased HTT production in those with advanced disease or higher disease burden: the
CAG expansion may result in aberrantly-spliced isoforms of HTT exon1 mRNA that are trans-
lated into N-terminal fragments [3, 33]. Additionally, full-length HTT may be proteolytically
cleaved to form these N-terminal mHTT fragments [2].
Somatic instability has been implicated in the pathogenesis of HD [34]. While historically
somatic expansion was not detected in blood cells [35] it does occur in lymphoblasts [29] and
we cannot exclude the possibility that it may be detected in blood using new techniques. Even
if somatic instability does occur in blood, however, it is unlikely to be sufficient to account for
the observed increase in polyQ dependent binding, since the assays are more dependent upon
concentration than polyQ length. By way of illustration, consider that an overall increase from
40 to 50 glutamines might be needed to account for the 33.1% and 22.3% increases we observe
between premanifest and manifest in samples sets 1 and 2 respectively. This is because the
valency of MW1 is ~10 glutamines [22], so an increase from 40 to 50 glutamines might enable
5 rather than 4 antibodies to bind, giving a 25% increase in signal.
A positive correlation between mHTT and disease burden had previously been demon-
strated in monocytes, B cells and T cells [13]; however, that study did not adjust for CAG in its
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main analysis. Without CAG in the model, we found DBS was associated with mHTT in sam-
ple set 2. However this association became non-significant with the addition of CAG. With
both CAG and age controlled for in our model, DBS is equivalent to an interaction term
between CAG and age. The non-significance of this term means we have found no evidence
that the effect of CAG on HTT changes with age, or that the effect of age on HTT changes with
CAG. Although non-significant, the estimate was still in the expected direction; the presence
of multiple cell populations in our study may increase variance, meaning the present study was
not powered to detect a relationship between DBS and mHTT in PBMCs, and suggesting that
a larger cohort would be needed to examine this. CAG repeat length was found to be positively
associated with mHTT level in the larger sample set 2. Increased length of the polyglutamine
expansion is associated with increased MW1 antibody binding [16, 22], but our study includes
only a narrow range of repeat sizes (standard deviation 3.40), meaning this effect is unlikely to
account for the results. Intriguingly there was a significant relationship between the polygluta-
mine independent N-terminal fragment of Huntingtin and disease burden in sample set 2, and
a significant relationship of small effect with CAG repeat length. Although interesting, it is
plausible that this is simply a chance finding, as we explored many associations and did not
make any corrections to our significance level for multiple testing.
mHTT was lower in women than men in sample set 2, and there were parallel, though non-
significant, relationships between HTT species and sex in all assays. HD phenotypic measures
have previously been shown to have complex relationships with sex [36]. However it is also
possible that our findings are due to haemodynamic differences between males and females
[37, 38].
In summary, we have confirmed the previously reported findings of an increase in soluble
mHTT with disease stage in patient blood cells, though for the first time in PBMCs. PBMCs
are readily available, making this assay amenable to large-scale clinical studies and trials. The
MSD electrochemiluminescence immunoassay platform is sensitive, can be validated for clini-
cal trial use, and is standardisable across sites. We conclude that these assays have potential as
a means of understanding the role of different HTT protein species ex vivo and warrant further
investigation for use in HTT-modulating therapeutic studies.
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